SSY GROUP (02005.HK): Bevantolol Hydrochloride Cleared as API, the Third Domestic Approval

NewTimeSpace News: On 13 November 2026, SSY GROUP (02005.HK) said in a voluntary announcement that its bevantolol hydrochloride has been approved by China's National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed formulations, making the Group the third domestic company to obtain such approval.

The product is indicated mainly for essential hypertension and is a new-generation highly selective alpha1 and beta1 dual receptor blocker. It blocks cardiac beta1 receptors to steady the heart rate and reduce myocardial contractility, and blocks vascular alpha1 receptors to dilate peripheral vessels and lower vascular resistance, while inhibiting renin release, so that blood pressure is held steady over 24 hours.

The announcement described the product as a hypertension drug with a comprehensively upgraded mechanism. The Company said the disclosure was made voluntarily to keep shareholders and potential investors informed of the Group's latest business developments.